StemCell Therapy

Rajasekharreddy Pala,1,2 VT Anju,3 Madhu Dyavaiah,3 Siddhardha Busi,4 Surya M Nauli1,2

1Department of Biomedical and Pharmaceutical Sciences, Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, CA 92618, USA; 2Department of Medicine, University of California Irvine, Irvine, CA 92868, USA; 3Department of Biochemistry and Molecular Biology, School of Life Sciences, Pondicherry University, Puducherry, India; 4Department of Microbiology, School of Life Sciences, Pondicherry University, Puducherry, India

Correspondence: Rajasekharreddy Pala; Surya M Nauli Tel +714-516-5462; +714-516-5480Fax +714-516-5481Email rrpala@chapman.edu; nauli@chapman.edu

Abstract: Cardiovascular diseases (CVDs) are one of the foremost causes of high morbidity and mortality globally. Preventive, diagnostic, and treatment measures available for CVDs are not very useful, which demands promising alternative methods. Nanoscience and nanotechnology open a new window in the area of CVDs with an opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues. The application of nanoparticles and nanocarriers in the area of cardiology has gathered much attention due to the properties such as passive and active targeting to the cardiac tissues, improved target specificity, and sensitivity. It has reported that more than 50% of CVDs can be treated effectively through the use of nanotechnology. The main goal of this review is to explore the recent advancements in nanoparticle-based cardiovascular drug carriers. This review also summarizes the difficulties associated with the conventional treatment modalities in comparison to the nanomedicine for CVDs.

Keywords: cardiovascular diseases, nanoscience, nanoparticles, nanomedicine, nanocarriers, treatment

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascula | IJN - Dove Medical Press

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

See the rest here:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and... - Azizsalon News

New York, May 27, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nanotechnology in Drug Delivery Industry" - https://www.reportlinker.com/p05621749/?utm_source=GNW 1 Billion by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Nanocrystals market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 17% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$4.1 Billion to the regions size over the next 7 to 8 years. In addition, over US$3.7 Billion worth of projected demand in the region will come from Rest of European markets. In Japan, the Nanocrystals segment will reach a market size of US$3 Billion by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Nanotechnology in Drug Delivery market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the worlds second largest economy will grow at 25.2% over the next couple of years and add approximately US$20.2 Billion in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Nanotechnology in Drug Delivery market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, AbbVie Inc.; Aquanova AG; BlueWillow Biologics; Camurus AB; Celgene, Inc.; Ceramisphere Health Pty Limited; Cristal Therapeutics; CYTIMMUNE SCIENCES, Inc.; EnColl Corporation; EyePoint Pharmaceuticals; Lena Nanoceutics Ltd.; Nanobiotix; NanoCarrier Co., Ltd.; NanOlogy LLC; Nanospectra Biosciences, Inc.; Parvus Therapeutics Inc.; Selecta Biosciences; Starpharma Holdings Limited; Taiwan Liposome Co., ; Tarveda Therapeutics

Read the full report: https://www.reportlinker.com/p05621749/?utm_source=GNW

NANOTECHNOLOGY IN DRUG DELIVERY MCP-7MARKET ANALYSIS, TRENDS, AND FORECASTS, JUNE 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Nanotechnology, A Critical Part of Healthcare Reform Recent Market Activity Nanomedicine, Revolutionizing the Basics of Medicine A Peek Into the Evolving Role of Nanoparticles in Nanomedicine Nanocrystals Continue to Gain Momentum as Alternatives to Traditional Nanocarriers Nanocarriers Enable Targeted Drug Delivery Systems to Improve Therapeutic Outcomes Advanced Liposomes Enable Low Soluble Drugs to Achieve Targeted Delivery Multifunctional Dendrimers Present an Ideal Structure for Targeted Drug Delivery High Drug Loading Capacity of PAMAM Dendrimers Bodes Well for Targeted Drug Delivery Systems Nanotechnology-Based Strategies for siRNA Grows in Popularity NEM Devices as Drug Delivery Vehicles Nanotechnology - In Pursuit of Co-Delivery of Drugs Nanoemulsions Begin to Make a Mark Nanotechnology Finds Increasing Role in Fighting Infectious Diseases List of Select Nanotechnology-based Antimicrobial Drugs in Clinical Use Nanotechnology Opening New Avenues in Antiretroviral Therapy Demonstrated Activity of Select Nanotechnology- Delivered Antiretroviral Therapies Nanotechnology in Delivery of CNS Therapeutics Market Outlook Global Competitor Market Shares Nanotechnology in Drug Delivery Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS AbbVie Inc. (USA) Aquanova AG (Germany) BlueWillow Biologics (USA) Camurus AB (Sweden) Celgene, Inc. (Canada) Ceramisphere Health Pty Limited (Australia) Cristal Therapeutics (The Netherlands) CYTIMMUNE SCIENCES, INC. (Italy) EnColl Corporation (USA) EyePoint Pharmaceuticals (USA) Lena Nanoceutics Ltd. (UK) NanOlogy LLC (USA) NanoCarrier Co., Ltd. (Japan) Nanobiotix (France) Nanospectra Biosciences, Inc (USA) Parvus Therapeutics Inc. (USA) Selecta Biosciences (USA) Starpharma Holdings Limited (Australia) Taiwan Liposome Co. (Taiwan) Tarveda Therapeutics (USA) 3. MARKET TRENDS & DRIVERS Growing Need for Alternative Approaches to Conventional Chemotherapy Creates Opportunities for Nanoparticles Stimuli Responsive Polymeric Micelles Promise Enhanced Therapeutic Effect for Hydrophobic Anticancer Drugs Inorganic Nanocarriers Facilitate High Payload Capacity and Co -Delivery Platforms for MDR Cancer Therapy Solid Lipid Nanoparticles Provide Increased Physical Stability in Targeted Drug Delivery Pulmonary Delivery of Nanoparticle-Based Drugs Receives Increased Interest Inhalable Liposome Formulations Attract Research Interest in Pulmonary Delivery SLNs in Pulmonary Delivery of Drugs Market Challenges Increasing Environmental and Health Concerns Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement Higher Concentration of Research in Academia limits Commercialization Collaborations Assume Importance Nanomedicine Regulation 4. GLOBAL MARKET PERSPECTIVE Table 1: Nanotechnology in Drug Delivery Global Market Estimates and Forecasts in US$ Million by Region/Country: 2020-2027 Table 2: Nanotechnology in Drug Delivery Market Share Shift across Key Geographies Worldwide: 2020 VS 2027 Table 3: Nanocrystals (Technology) World Market by Region/Country in US$ Million: 2020 to 2027 Table 4: Nanocrystals (Technology) Market Share Breakdown of Worldwide Sales by Region/Country: 2020 VS 2027 Table 5: Nanocarriers (Technology) Potential Growth Markets Worldwide in US$ Million: 2020 to 2027 Table 6: Nanocarriers (Technology) Market Sales Breakdown by Region/Country in Percentage: 2020 VS 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Nanotechnology in Drug Delivery Market Share (in %) by Company: 2020 & 2025 Market Analytics Table 7: Nanotechnology in Drug Delivery Market in US$ Million in the United States by Technology: 2020-2027 Table 8: United States Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 CANADA Table 9: Nanotechnology in Drug Delivery Market Analysis in Canada in US$ Million by Technology: 2020-2027 Table 10: Canadian Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 JAPAN Table 11: Japanese Medium & Long-Term Outlook for Nanotechnology in Drug Delivery Market in US$ Million by Technology: 2020-2027 Table 12: Japanese Nanotechnology in Drug Delivery Market Percentage Share Distribution by Technology: 2020 VS 2027 CHINA Table 13: Nanotechnology in Drug Delivery Market Estimates and Forecasts in China in US$ Million by Technology: 2020-2027 Table 14: Nanotechnology in Drug Delivery Market in China: Percentage Share Analysis by Technology for 2020 and 2027 EUROPE Market Facts & Figures European Nanotechnology in Drug Delivery Market: Competitor Market Share Scenario (in %) for 2020 & 2025 Market Analytics Table 15: European Nanotechnology in Drug Delivery Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 16: European Nanotechnology in Drug Delivery Market Share Shift by Region/Country: 2020 VS 2027 Table 17: European Nanotechnology in Drug Delivery Market Assessment in US$ Million by Technology: 2020-2027 Table 18: Nanotechnology in Drug Delivery Market in Europe: Percentage Breakdown of Sales by Technology for 2020 and 2027 FRANCE Table 19: French Nanotechnology in Drug Delivery Market Estimates and Projections in US$ Million by Technology: 2020-2027 Table 20: French Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 GERMANY Table 21: German Nanotechnology in Drug Delivery Latent Demand Forecasts in US$ Million by Technology: 2020-2027 Table 22: German Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 ITALY Table 23: Nanotechnology in Drug Delivery Market Estimates and Forecasts in Italy in US$ Million by Technology: 2020-2027 Table 24: Nanotechnology in Drug Delivery Market in Italy: Percentage Share Analysis by Technology for 2020 and 2027 UNITED KINGDOM Table 25: United Kingdom Medium & Long-Term Outlook for Nanotechnology in Drug Delivery Market in US$ Million by Technology: 2020-2027 Table 26: United Kingdom Nanotechnology in Drug Delivery Market Percentage Share Distribution by Technology: 2020 VS 2027 SPAIN Table 27: Nanotechnology in Drug Delivery Market Analysis in Spain in US$ Million by Technology: 2020-2027 Table 28: Spanish Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 RUSSIA Table 29: Nanotechnology in Drug Delivery Market in US$ Million in Russia by Technology: 2020-2027 Table 30: Russian Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 REST OF EUROPE Table 31: Rest of Europe Nanotechnology in Drug Delivery Market Assessment in US$ Million by Technology: 2020-2027 Table 32: Nanotechnology in Drug Delivery Market in Rest of Europe: Percentage Breakdown of Sales by Technology for 2and 2027 ASIA-PACIFIC Table 33: Asia-Pacific Nanotechnology in Drug Delivery Market Estimates and Forecasts in US$ Million by Region/Country: 2020-2027 Table 34: Asia-Pacific Nanotechnology in Drug Delivery Market Share Analysis by Region/Country: 2020 VS 2027 Table 35: Asia-Pacific Nanotechnology in Drug Delivery Market Estimates and Projections in US$ Million by Technology: 2020-2027 Table 36: Asia-Pacific Nanotechnology in Drug Delivery Historic Market Analysis in US$ Million by Technology: 2020 VS 2027 AUSTRALIA Table 37: Australian Nanotechnology in Drug Delivery Latent Demand Forecasts in US$ Million by Technology: 2020-2027 Table 38: Australian Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 INDIA Table 39: Nanotechnology in Drug Delivery Market Analysis in India in US$ Million by Technology: 2020-2027 Table 40: Indian Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 SOUTH KOREA Table 41: Nanotechnology in Drug Delivery Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Technology for the Period 2020-2027 Table 42: Nanotechnology in Drug Delivery Market Share Distribution in South Korea by Technology: 2020 VS 2027 REST OF ASIA-PACIFIC Table 43: Rest of Asia-Pacific Medium & Long-Term Outlook for Nanotechnology in Drug Delivery Market in US$ Million by Technology: 2020-2027 Table 44: Rest of Asia-Pacific Nanotechnology in Drug Delivery Market Percentage Share Distribution by Technology: 2020 VS 2027 LATIN AMERICA Table 45: Latin American Nanotechnology in Drug Delivery Market Trends by Region/Country in US$ Million: 2020-2027 Table 46: Latin American Nanotechnology in Drug Delivery Market Percentage Breakdown of Sales by Region/Country: 2020 and 2027 Table 47: Nanotechnology in Drug Delivery Market Estimates and Forecasts in Latin America in US$ Million by Technology: 2020-2027 Table 48: Nanotechnology in Drug Delivery Market in Latin America : Percentage Analysis by Technology for 2020 and 2027 ARGENTINA Table 49: Argentinean Nanotechnology in Drug Delivery Market Assessment in US$ Million by Technology: 2020-2027 Table 50: Nanotechnology in Drug Delivery Market in Argentina: Percentage Breakdown of Sales by Technology for 2020 and 2027 BRAZIL Table 51: Brazilian Nanotechnology in Drug Delivery Market Estimates and Projections in US$ Million by Technology: 2020-2027 Table 52: Brazilian Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 MEXICO Table 53: Mexican Nanotechnology in Drug Delivery Latent Demand Forecasts in US$ Million by Technology: 2020-2027 Table 54: Mexican Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 REST OF LATIN AMERICA Table 55: Nanotechnology in Drug Delivery Market in US$ Million in Rest of Latin America by Technology: 2020-2027 Table 56: Rest of Latin America Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 MIDDLE EAST Table 57: The Middle East Nanotechnology in Drug Delivery Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 58: The Middle East Nanotechnology in Drug Delivery Market Share Breakdown by Region/Country: 2020 and 2027 Table 59: The Middle East Nanotechnology in Drug Delivery Market Analysis in US$ Million by Technology: 2020-2027 Table 60: The Middle East Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 IRAN Table 61: Iranian Medium & Long-Term Outlook for Nanotechnology in Drug Delivery Market in US$ Million by Technology: 2020-2027 Table 62: Iranian Nanotechnology in Drug Delivery Market Percentage Share Distribution by Technology: 2020 VS 2027 ISRAEL Table 63: Israeli Nanotechnology in Drug Delivery Market Assessment in US$ Million by Technology: 2020-2027 Table 64: Nanotechnology in Drug Delivery Market in Israel: Percentage Breakdown of Sales by Technology for 2020 and 2027 SAUDI ARABIA Table 65: Nanotechnology in Drug Delivery Market Estimates and Forecasts in Saudi Arabia in US$ Million by Technology: 2020-2027 Table 66: Nanotechnology in Drug Delivery Market in Saudi Arabia: Percentage Share Analysis by Technology for 2020 and 2027 UNITED ARAB EMIRATES Table 67: Nanotechnology in Drug Delivery Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Technology for the Period 2020-2027 Table 68: Nanotechnology in Drug Delivery Market Share Distribution in United Arab Emirates by Technology: 2020 VS 2027 REST OF MIDDLE EAST Table 69: Rest of Middle East Nanotechnology in Drug Delivery Latent Demand Forecasts in US$ Million by Technology: 2020-2027 Table 70: Rest of Middle East Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 AFRICA Table 71: Nanotechnology in Drug Delivery Market in US$ Million in Africa by Technology: 2020-2027 Table 72: African Nanotechnology in Drug Delivery Market Share Breakdown by Technology: 2020 VS 2027 IV. COMPETITION

Total Companies Profiled: 43 Read the full report: https://www.reportlinker.com/p05621749/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Follow this link:
Amid the COVID-19 crisis and the looming economic recession, the Nanotechnology in Drug Delivery market worldwide will grow by a projected US$124.7...

President Donald Trump pondered if he should take insulin while announcing a plan to reduce the price of the drug typically prescribed to diabetics. USA TODAY

WASHINGTON President Donald Trump pondered on Tuesday whether he should be taking insulin,a hormone typically prescribed to diabetics, during an announcement foraplan which would aim to drastically reduce the price of insulin for people on Medicare.

"I don't use insulin," Trump said. "Should I be? Huh? I never thought about it. But I know a lot of people are very badly affected, right? Unbelievable."

In people with Type 1 diabetes, the pancreas cant make insulin. Those with the condition require several doses of insulin a day.

'Contain potentially misleading information': Twitter fact-checks Trump's tweets

All people with Type 1 and some with Type 2, whose body doesnt use insulin the way it should, need the drug.

Trump has no known history of diabetes.

More than 30.3 million people in the U.S. have diabetes, and 90% to 95% of them have Type 2 diabetes, according to the 2017 National Diabetes Statistics Report. Unlike people with Type 1 diabetes, those with Type 2 can in many caseslessen their dependence on insulin through healthier diet and exercise.

Clyburn: I 'cringed' at Biden 'you ain't black' comment but compare him 'to the alternative, not the Almighty'

Asked later by a reporter why he would take insulin, Trump asked surgeon general Jerome Adams to answer, in which he explained to the president that, "Your body, Mr. President, actually makes insulin endogenously."

He continued that "people such as you and I, we make our own insulin. So yes we do utilize insulin, but we make it ourselves.

Trump saysmost senior Medicare recipients willget prescription plans that would cap copay costs, giving them access to several types of insulinat no more thana $35 copayfor a month's supply, underneath the planannounced Tuesday.

Struggling to stay alive: Rising insulin prices cause diabetics to go to extremes

The price of modern versions of a drug that more than 7 million Americans need to livenearly tripled from 2002 to 2013, according to onestudy.Type 1 diabetics paid an average of $5,705 for insulin in 2016 nearly double what they paid in 2012, according to the Health Care Cost Institute.

Costs for insulin have continuedto rise, so much so that almost half of people with diabeteshave temporarily skipped taking their insulin, according to a 2018 survey by UpWell Health, a Salt Lake City company that provides home delivery of medications and supplies for chronic conditions.

Contributing:Ken Alltucker, USA TODAY;Megan Henry, The Columbus Dispatch.

Read or Share this story: https://www.usatoday.com/story/news/politics/2020/05/26/trump-asks-whether-he-should-taking-insulin-despite-not-being-diabetic/5263965002/

Visit link:
Trump asks whether he should take insulin despite not being diabetic - USA TODAY

DUBLIN--(BUSINESS WIRE)--he "United States Diabetic Food Market By Product Type (Baked Products For Diabetics, Beverages For Diabetics, Confectionery For Diabetics, Ice Cream For Diabetics, Others), By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The United States Diabetic Food Market is expected to grow at a formidable rate of during the forecast period. The United States Diabetic Food Market is driven by the growing awareness regarding various health issues associated with diabetes, increasing prevalence of obesity and diabetes owing to a lack of physical activity among children and adolescents, rising awareness among consumers regarding the preventive measures that can be taken against diabetes, among others. Additionally, growing research and development (R&D) to produce diabetic food products and flaunting a diversified product portfolio that caters to the requirements of a wide consumer base is further expected to propel the market during forecast years.

The United States Diabetic Food Market is segmented based on product type, distribution channel, end-user, company and region. Based on product type, the market can be fragmented into baked products for diabetics, beverages for diabetics, confectionery for diabetics, ice cream for diabetics, dairy products for diabetics and breakfast cereals for diabetics. The beverages for diabetics segment is expected to dominate the market during the next five years. This can be ascribed to the varied products available under dietary beverages and relatively large consumption of these beverages.

Companies Mentioned

Objective of the Study:

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. United States Diabetic Food Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Product Type (Baked Products For Diabetics, Beverages For Diabetics, Confectionery For Diabetics, Ice Cream For Diabetics, Dairy Products For Diabetics and Breakfast Cereals For Diabetics)

5.2.2. By Distribution Channel (Grocery Stores, Supermarkets/Hypermarkets, Online, Drug Stores/Pharmacies and Others)

5.2.3. By End Users (Adults v/s Children)

5.2.4. By Region

5.2.5. By Company (2018)

5.3. Product Market Map

6. United States Baked Products For Diabetics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Distribution Channel

6.2.2. By End Users

7. United States Beverages For Diabetics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Distribution Channel

7.2.2. By End Users

8. United States Confectionery For Diabetics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Distribution Channel

8.2.2. By End Users

9. United States Ice Cream For Diabetics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Distribution Channel

9.2.2. By End Users

10. United States Dairy Products For Diabetics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Distribution Channel

10.2.2. By End Users

11. United States Breakfast Cereals For Diabetics Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Distribution Channel

11.2.2. By End Users

12. Market Dynamics

12.1. Drivers

12.2. Challenges

13. Market Trends & Developments

14. Supply Chain Analysis

15. Policy & Regulatory Landscape

16. United States Economic Profile

17. Competitive Landscape

17.1. Competition Outlook

17.2. Company Profiles

18. Strategic Recommendations

19. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/wgptnq

See the original post:
Insights on the US Diabetic Food Industry to 2025 - Featuring Unilever, Kellogg Company & Fifty 50 Foods Among Others - ResearchAndMarkets.com -...

By: Lifestyle Desk | New Delhi | Updated: May 27, 2020 3:26:32 pm It is the need of the hour to keep the sugar levels in check for the ones with diabetes as the cases of Covid-19 is increasing speedingly. (Source: Getty/Thinkstock/Pixabay images)

If one gets diabetes, not only does their blood sugar level get affected, but the insulin production level also gets compromised. People with high or unmanaged blood sugar levels tend to have less than normal blood flow, because of which the body finds it difficult to harness nutrients and heal. Thus, due to the weakened immune system, people suffering from diabetes are prone to infections, and may take a longer time to get back on track. The condition, however, is manageable, even in the wake of coronavirus.

It is the need of the hour to keep the sugar levels in check for the ones with diabetes as the cases of Covid-19 increase stupendously.

* Stay hydrated, and eat fresh fruits and vegetables to enhance your immunity.

* Exercise on a daily basis. Try to increase activities at home. Do exercises that will not stress you out. Opt for yoga, pranayama, and deep breathing exercises. This will improve your pulmonary function and will not cause any disturbance in breathing. Even light stretches can be done to keep your body supple and fit. You can also do simple household chores such as sweeping, mopping, and cleaning, suggests Dr Anil Boraskar, Diabetologist, ACI Cumballa Hill Hospital, Mumbai.

* Check blood sugar level at home with the help of home glucose monitoring that is reliable machines. You can check your blood sugar levels and keep a target of less than 140 and 180 mg/dl. If your sugar is in this range then monitor the levels, every alternate day. If your sugar levels are not in this range then monitor it thrice a day, and you will have to take insulin instead of medications. Consult your diabetologist over the phone, who will set your insulin doses according to your blood sugar levels.

* If you are diabetic and hypertensive, then monitor your blood pressure levels from time to time and take medications.

* Washing hands is important, and so is washing feet. Clean them regularly. You can take the help of your family members and look for any cuts, ulcers, or wounds on the feet. Get immediate attention if required.

* Maintain good personal hygiene. Upgrade your skin, oral, and intimate hygiene. Practice social distancing.

* The spread of COVID-19 is via asymptomatic patients in whom symptoms are not seen. But if you are a diabetic and have a seasonal cough or cold then pay attention to it. Other symptoms that people with diabetes may have is hypoglycemia (can be described as a condition in which your blood sugar (glucose) level is lower than normal). This can be dangerous so help yourself with sugar if your sugar is less than 70 mg/dL. Make a note of what has caused a drop in your sugar level, says Dr Boraskar, Diabetologist.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

See original here:
Tips for diabetes patients to manage their blood sugar - The Indian Express

By: Lifestyle Desk | New Delhi | Updated: May 25, 2020 11:56:59 am Heres how to keep a check on your sugar levels. (Source: Getty Images/Thinkstock)

Physical fitness is a state of health and well-being and, more specifically, the ability to perform various daily tasks efficiently. Which is why it is essential for every individual to stay fit and eat healthy. And when it comes to diabetics, maintaining sugar levels and fitness becomes the most important aspect, suggests Dr Pramod Tripathi, founder, Freedom from Diabetes.

Diabetics should remember to take care of their diet, exercise and mental health.

*Maintain a balanced diet plan and follow it religiously.*Eat calculated amount of calories to meet the bodys requirement. This will help achieve ideal/desirable body weight.*As far as possible, try to eat high fibre foods (whole grains, pulses, and all green vegetables) as well as greens and vegetables. During meals, take equal quantity of grain, dal, cooked vegetables and salads.*Eat less fruits.*Eat diet which is low in glycemic index to keep blood sugar levels within desired range.*Filtered mustard oil, groundnut oil, rice bran oil and gingelly oil should be preferred. Olive oil is best used for salads.*Drink sufficient amount of water. 250 ml per 10 kg body weight.*Sleep before 11pm.

Diabetics should concentrate more on exercise than diet, suggests Dr Tripathi. They should do:

*Full range of motion (ROM) exercises neck exercises, head tilts, forward and back and side-to-side and head turns, arms and elbow exercise, hip and waist twisting, leg movements*Chair Surya Namaskar or regular Surya Namaskar at least 6-12 times per day*Chair-based exercises (yoga and stretching)*Stair climbing two hours after meals brings blood sugar under control rapidly (100-300 steps)*Skipping ropes (if knees are in good shape, and weight under control)*15-20 minute walking can be done everyday*Deep breathing exercises (pranayamas)*Minimum 30 minutes of workout should be included in daily routine.

ALSO READ | Coronavirus pandemic: Easy tips for diabetics to stay safe | New form of insulin may improve diabetes treatment: Study | Time in range: The new metric that can help diabetics prevent long-term complications

*Along with diet and exercise, mental health is equally important. With the current lifestyle, there is also a lot of stress and negativity around, and one should be careful.

*To release the stored stress and continual stress on a day-to-basis, whole brain posture meditation is advisable. In this, one is made to sit in a particular way, concentrate on bad memories, feel them in the body, make strong intention to relieve them. This way they start getting released.

*Besides whole brain posture meditation, there is Breathwork meditation and soul-mind-body healing which are also very useful tools for dealing with stress and negativity.

*All the above will help you in releasing the negativity which in turn helps bring positivity, suggests Dr Tripathi.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

View post:
Diabetic? Tips to keep your blood sugar levels in check amid pandemic - The Indian Express

HIGH POINT, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Associations 80th Scientific Sessions, which is being held virtually, June 1216, 2020.

In February 2020 the Company announced positive topline results from its Phase 2 (Part 2) Simplici-T1 trial showing that TTP399 lowered HbA1c, decreased insulin dose, and increased Time in Range in patients with type 1 diabetes (T1D).

Details of the virtual presentations which will provide full clinical study data from that trial follow:

Late-Breaking Poster Title: The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 DiabetesPoster Number:122-LBCategory: 12-F Clinical Therapeutics/New TechnologyOther Therapeutic Agents.Date and Time:Saturday, June 13, 2020,10:00 AM CT (11:00 AM ET)

Late-Breaking Poster Title: The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin DosePoster Number:123-LBCategory: 12-F Clinical Therapeutics/New TechnologyOther Therapeutic Agents.Date and Time:Saturday, June 13, 2020, 10:00 AM CT (11:00 AM ET)

About the Simplici-T1 StudySimplici-T1 was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D. The primary endpoint was the change in HbA1c at week 12.The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes.

This Phase 2 learn-and-confirm study was conducted in two parts under a treat-to-target protocol to evaluate the safety and efficacy of TTP399 in T1D patients over 12 weeks of daily dosing following a multi-week insulin optimization and placebo run-in period. Part 1 enrolled 19 patients on both insulin pumps and CGMs. The positive topline results from the learning phase - Part 1 were reported inJune, 2019. The confirming phase, Part 2, enrolled 85 patients that used either insulin pumps or multiple daily injections of insulin; CGMs were allowed for those patients using the devices for at least three months prior to the start of the study.

About Type 1 DiabetesType 1 diabetes is an autoimmune disease in which a persons pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the bodys immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, andat presentnothing you can do to cure it.

AboutvTv TherapeuticsvTv Therapeutics Inc.is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimers disease, and inflammatory disorders. vTvs development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit http://www.vtvtherapeutics.comor follow us on Twitter: @vTvTherapeutics.

Forward-Looking StatementsThis release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading Risk Factors in our Annual Report on Form 10-K and our other filings with theSEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Nura StrongVP of Business Developmentnstrong@vtvtherapeutics.com

See original here:
vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral...

There are plenty of reasons to adopt a low-sugar diet, including diabetes or a keto or paleo lifestyle. But whatever your reason, thesecookbooks make eating well easy and delicious.

I have a friend who was recently diagnosed with diabetes, which was sad for a number of reasons. It's a whole new lifestyle to adjust to, especially because my friend is such a foodie. She loves trying new things and taking pictures of all the beautiful and delicious food experiences she shares with her loved ones. So after her diagnosis, I picked up a diabetes-friendly cookbook for her to show her that even though her diet is much more restricted, she can still be as adventurous with foods as she once was.

While I was doing my research to make sure my friend would be fine to eat the meals in her cookbook, I found that the diet diabetics follow is similar to the paleo and keto diets, in that they are low in sugar and carbs. So, whether you need to cut sugar out for health reasons or are looking to experiment with a new diet, these cookbooks are all worth picking up and diving into.

This cookbook was written by a dietician and diabetes expert, so it includes the newest information we have about managing diabetes in the context of the meals you eat. It includes both meal plans and hundreds of recipes that will prevent any serious side effects a newly diagnosed diabetic may be afraid of. It also helps that, even though they are low in sugar and carbs, these meals -- like the salmon, quinoa and avocado salad and herbed chicken meatball wraps -- are delicious.

Anything Betty Crocker is bound to be flavorful, homey and delicious. If you've been diagnosed with diabetes, let this cookbook be a reminder that you don't have to give up any of your favorite meals. In this book, you'll find plenty of breakfasts, lunches and dinners (including blueberry-almond brown bread, pork chops with raspberry-chipotle sauce and herbed rice and even pumpkin-chocolate chip cookies) you can eat until you're good and full.

While this cookbook is similar to the others in that it contains well-rounded and health-conscious recipes for a diabetic, I like that it also contains budgeting advice. With more and more doctor's appointments, treatments and equipment to pay for just to keep your diabetes under control, money may betighter than you'd like to admit. With a built-in budgeting guide, this book assures you that you don't have to break the bank for your new dietary lifestyle.

It simply is not possible to go without dessert. Luckily, there are tons of cookbooks like this one that focus just on desserts. But don't worry -- all the recipes in this book are perfectly healthy for diabetics. The sweets in this book -- which include mocha fudge cake and peach crumble -- are healthy anddelicious and the recipes are easy to follow.

Even though we are now moving into keto (and, eventually, paleo) cookbooks, I just want to mention that most -- if not all -- of the recipes in the following cookbooks are healthy for diabetics as well. Keto and paleo diets follow a low-carb and low-sugar regimen that coincides with diabetic diets. However, if you are unsure, definitely consult your doctor and make sure you're monitoring your blood levels.

This cookbook is great because all the recipes are keto-friendly, but they are also perfect for anyone who's on-the-go and perpetually busy. You'll find recipes with five or fewer ingredients, meals that can be made in 30 minutes or less and entire meals that can all be prepared in one pot, including a BLT breakfast salad, garlic butter shrimp and berry cheesecake fat bombs.

Instant Pots remain wildly popular because they are so versatile in how you can use them -- and, of course, you can make amazing meals with little to no effort. If you got an Instant Pot and are now afraid that your new diet may limit your ability to use it, have no fear! This cookbook has plenty of Instant Pot recipes the whole family will love -- like deep-dish pizza dip, cauliflower and bacon chowder and southern sugar pie -- that are all keto-friendly, so you won't get bored on your diet any time soon.

Meal prepping is a huge part of dieting. You prepare well-portioned, healthy meals so that you have lunch and dinner for the week and you're not tempted to eat fast food on the run. When you start your keto diet, you may also want to start meal prepping to ensure that you're sticking to your plan. Try this cookbook that focuses on the meal prepping process and is in line with the keto diet. Recipes include ham and cheese breakfast muffins, Italian zucchini boats and pork burrito bowls.

While the title of this cookbook only mentions the keto diet, it is advertised as perfectly good for paleo and diabetic diets as well. Even people on seriously restricted diets need a little something sweet every now and again -- and what better than ice cream as we head into the summer months? Make healthy ice cream and frozen treats including strawberry cheesecake pops, apricot sherbet and chocolate avocado ice cream with this book.

Like Instant Pots, spiralizers have gotten a lot of attention in the past few years. Spiralizers allow you to finely slice vegetables so that they have the consistency and appearance of noodles. People replace regular pasta (which is high in carbs) with these vegetable noodles for a healthier, paleo-friendly option, which works great for keto and diabetic diets, too. Featuring several different vegetables -- including beets, carrots, butternut squash, sweet potatoes, cucumbers, broccoli, turnips, cabbage and bell peppers. With recipes including creamy fettuccini alfredo, turnip curly fries and cucumber noodle poke bowls, this cookbook will help you master your spiralizer while sticking to your diet in the most delicious way possible.

I'm a big fan of "for beginners" cookbooks because they do a great job of teaching you about your new diet and offering delicious meals that motivate you to stick to it. So whether you've just been diagnosed with diabetes or you're thinking of starting the paleo diet, this cookbook (with recipes including high-protein grain-free burgers, buffalo chicken wraps and paleo waffles) is a great investment.

This cookbook, in addition to paleo meals, shopping lists and quick and easy-to-follow recipes (there's barbecue salmon with peach salsa, Peruvian-style chicken, meyer lemon curd cakes and no-cook chocolate pudding), contains additional options for gluten- and dairy-free meals. So even if you're just trying to avoid dairy, you'll find something great in this cookbook -- with slow cooker, one-pot and 30-minute recipes too.

You can't possibly think I forgot about dessert! This paleo-friendly cookbook is full of decadent and tasty cakes, cookies, doughnuts, waffles and more -- including vermont maple doughnuts, gingerbread pancakes and celebration chocolate cake -- all without grains, gluten, dairy or refined sugar. Who says you can't satisfy your sweet tooth while sticking to your diet?

This story was written by Toniann Pasqueralle for CNET's sister site Chowhound.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Continue reading here:
12 cookbooks with low-sugar recipes for diabetic, keto and paleo dieters - CNET

THOUSANDS of people in Swindon are in danger of becoming severely ill with coronavirus.

Those living with diabetes face a significantly higher risk of dying with Covid-19, with new NHS research revealing a third of deaths in England are associated with the condition.

More than 14,000 people in Swindon have diabetes, meaning it is more prevalent here than any other town in the South West. And that number could be set to soar almost 5,000 more without the condition are known to have high blood sugar levels.

The study showed people living with type 1 diabetes are at three-and-a-half times the risk of dying in hospital with the virus and those with type 2 are at double the risk, when compared to people without it.

But it found by far the strongest risk factor for dying with Covid-19 is age.

Professor Jonathan Valabhji, national clinical director for diabetes and obesity and lead author of the study, said: This research shows the extent of the risk of coronavirus for people with diabetes and the different risks for those with type 1 and type 2 diabetes.

Importantly, it also shows that higher blood glucose levels and obesity further increase the risk in both types of diabetes.

This can be worrying news but we would like to reassure people that the NHS is here for anyone with concerns about diabetes and has put extra measures in place to help people and keep them safe, including online sites to support people to care for themselves, digital consultations, and a dedicated new helpline for advice and support for people treated with insulin.

Diabetics are not in the 'clinically extremely vulnerable' shielding group.Instead, they are in the 'clinically vulnerable' group, which means they should follow stringent social distancing advice.

Diabetes UK director of policy Bridget Turner said: This new data sheds much-needed light on which groups of people with diabetes are more likely to experience poor outcomes if they catch coronavirus.

Its consistent with what we know about the impact of coronavirus on the general population; that poorer outcomes are very strongly linked to older age.

The numbers of people with all types of diabetes dying in hospital from coronavirus under the age of 40 were incredibly small, suggesting the risk for younger people is considerably lower.

It also shows that the risk of death for people with diabetes is higher than for people without the condition with the risk for people with type 1 being higher than for those with type 2 and that a history of higher blood sugar levels as well as obesity seem to be contributing factors.

Its very important to remember that the risk of dying from coronavirus for people with and without diabetes remains very low, and that as cases of coronavirus decline, the risk to everyone of catching the disease will reduce in turn.

Its also important to remember that the numbers of children and young people with type 1, and those under the age of 40 who have died from coronavirus are very small.

We know people with diabetes will want to know what they can do to keep themselves safe. The most important thing anyone with diabetes can do is try their best to manage their condition carefully, keeping their blood sugar in range as much as possible.

All people with diabetes should also follow stringent social distancing measures to reduce their chances of catching the virus altogether.

NHS Digital data from February showed 4,840 people registered with a GP in the NHS Swindon CCG area last year had non-diabetic hyperglycaemia the highest on record.

Those with NDH have high blood sugar levels, and are at greater risk of developing type 2 diabetes.

In Swindon, 5.1 per cent of those recorded as having non-diabetic hyperglycaemia were under 40

Last year the Adver reported 14,143 people in Swindon have diabetes a percentage of 7.59. The UK average is 6.8 per cent.

The council's cabinet member for adults and heath Brian Ford said: The number of people at risk of developing type 2 diabetes is on the increase nationally and a number of initiatives have been set up to combat it.

In Swindon, we have signed up to the National Diabetes Prevention Programme and, since 2017, more than 3,000 people have been referred.

On average, people who attend the nine-month programme lose 3.4kg.

The programme offers free advice and support to bring about changes in peoples lifestyles including nutritional support and access to physical activity.

All those enrolled on the programme are supported to reduce their risk of type 2 diabetes and, at the same time, given the motivation and confidence to address a range of conditions associated with being overweight as well as advice on how to eat healthily and to move to a more active lifestyle.

There were almost two millions diabetics in England last year.

See the article here:
Thousands of diabetics at higher risk of dying from coronavirus - Swindon Advertiser

Ben Coker is not 100% certain but the Lincoln left-back, who is on loan at Cambridge, thinks he is the only diabetic player in the English professional game. There might be a couple in the non-league that have played in the league but Im not sure whether there are any others in the Football League at the moment, Coker says. Thats the picture in England. I know that theres Nacho at Real Madrid. Hes type 1 diabetic. I found out about him a few years ago.

Coker was told at the age of 15 he had type 1 diabetes, the condition where the bodys immune system attacks and destroys the cells that produce insulin, although it has not stopped him from enjoying a long career in the sport he loves. Now 30, he is best known for his six seasons at Southend during which he made 208 appearances in all competitions.

Cokers underlying health condition and the daily need to manage it has come into even sharper focus during the Covid19 pandemic, with government advice recognising that people with diabetes can be more vulnerable to becoming seriously ill with the virus. With footballs restart or, more likely, non-start in Leagues One and Two a rolling news story, Coker has followed it with a particular perspective. With my condition, I have to think about it [the restart] probably more than other people would, he says.

Coker believes football should not be coming back any time soon and does not pull his punches on the subject. But he does not say so because of his diabetes, rather the fact he is about to become a father for the first time, and how he is more than anything worried about his family. For him, it comes down to basic humanity.

From a fans point of view, everyone wants to watch football because theres nothing else going on, but you have to look at us as human beings and say its not fair or right for us to be put in that situation where were going to be vulnerable to catching the virus, Coker says.

All its going to take is for someone to go down with it really badly and then, by the way, the legal side of it would be chaos. People do look at us sometimes as not being human beings but everyone has to be in the same boat.

With my diabetes, I know how to deal with it day to day if I do get ill, what I have to do with drink, food and monitoring it even that bit closer. In that sense, I would be OK with it [a return to playing]. But this is bigger than just me. My wife, Sarah, is nine months pregnant and me being in and around other people well, that would be my main concern. I have to look at my family, so I think its too soon to come back.

To play behind closed doors is not beneficial to League One and Two clubs. Ive come to the conclusion it won't happen

Coker knows the reality of the situation in Leagues One and Two. For largely financial reasons it is expected the competitions will be cancelled. Most clubs at this level cannot bear the cost of games without fans action behind closed doors is a government stipulation and nor will they be able to afford to test their players and staff with the requisite regularity.

But, Coker says, even the Premier League ought to rethink its mid-June comeback target. I think its too soon, Coker says. There is so much money coming into the game now and money rules the world in a certain way. It shouldnt be like that but it is. So I wouldnt be surprised if the Prem starts up again but for players at my level I cant see it. To play behind closed doors is not beneficial to any League One and Two clubs.

Also, if someone comes down with the virus, theyre going to have to isolate. There are so many things to think about and Ive come to the conclusion its not going to happen. If they cancel now, it will give us all a better chance of starting the next season at a normal time.

A consensus among players over a restart is difficult to find but does Coker feel his view is shared by his peers? I speak to my teammates and to be fair everyone is gagging to go back to football, he says. I miss the routine of day-to-day life, everyone does, but everyone also wants to be safe and well with their families. That comes into it massively.

If I was a single lad living on my own Id probably have a different opinion but you have to look at the bigger picture. We want it to be as short a period as possible before we get back to it but we have to do it in as safe a way as possible.

Coker speaks with a heavy heart. In October 2018, playing for Southend at Sunderland, he sustained a season-ending knee injury. I did a bit of everything my cruciate, my LCL and the meniscus, he says. And, soon after his move to Lincoln last summer, he tore his groin and needed a further operation. He has managed only one appearance this season for Lincoln in November.

In short, he is desperate to play again. But other things are more important.

The Guardian Sport

See original here:
Ben Coker: 'With Diabetes, I Have to Think About the Restart More Than Others' - Asharq Al-awsat - English

Ian Bolland caught up with the team at Insulet to find out more about Omnipod an insulin delivery system which a tubeless device that can provide three days of non-stop insulin delivery, and the app associated with it.

Give us a bit of background on Omnipod where did the idea come from?

Insulet, maker of the Omnipod insulin delivery system is headquartered in Massachusetts, and is an medical device company dedicated to simplifying the lives of people with diabetes through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its intuitively simple, wearable design, the disposable, waterproof Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. The Omnipod system actually came to be because a dad with a son newly diagnosed with diabetes said there has to be a better way to manage this disease. He sketched it out on the back of a napkin on a flight from California back to Boston almost 20 years ago. That same innovative approach has remained with the company ever since and is woven into the companys fabric and culture.

Who did you work with to bring the product to life?

Many passionate engineers, scientists, entrepreneurs, business men and women, and those with diabetes or impacted by diabetes in some way helped bring the Omnipod system to life.

What kind of material is the pod made out of?

The Pod is made out of durable medical grade materials and is made up of 72 individual components that all co-exist under the hood of the Pod. We work with many materials vendors locally and across the globe.

How do you wear the pod?

The Pod adheres to the body with a medical grade adhesive and can be placed anywhere a person may give themselves an insulin injection. Popular and FDA-approved sites include back of the arms, lower back/buttocks, thigh, and abdomen. The Pod is also fully waterproof which further simplifies life because there is no need to disconnect for water activities like swimming or bathing like you would with a traditional tubed insulin pump.

How does it actually help manage a persons insulin?

The Pod is worn on the body with no attachment to the hand-held controller (Personal Diabetes Manger, PDM). The Pod will deliver background basal insulin regardless of PDM location once programmed. The PDM is commonly carried in a separate carry case with all other supplies, kept in a gym bag, a locker, with the school nurse, in a purse, etc. Approximately 15 minutes before eating a meal or snack, a person would then use the PDM to deliver a mealtime bolus dose of insulin based on the amount of carbohydrates they are about to consume.

What happens after the three days of non-stop insulin delivery? Does it need topping up in some way?

The Pod has an automatic shut-off after 72 hours. There is a warning alarm to alert a user that they are approaching their 72-hour auto-shut off, at which point a person would deactivate their used Pod and activate a new Pod.

Give us an idea into the app behind it what kind of features does it have?

The Omnipod Display app allows for a convenient display of PDM data on the users iOS smartphone including; Pod status, insulin therapy history, and alarms, as well as a Find My PDM feature. The Omnipod Display app allows users to manage their diabetes with discretion and provides the ability to check their PDM dashboards from their personal mobile devices. Users may also invite up to 12 people to view their PDM data using the Omnipod View app.

The Omnipod View app provides caregivers and family members the ability to remotely monitor Omnipod Dash System data for their loved ones. The same Omnipod Dash System data that is displayed on a smartphone can be viewed on one or more additional smartphones remotely to stay informed and help manage loved ones diabetes. It also provides caregivers with important information such as last bolus, insulin on board, and any recent alerts.

The Omnipod Display app and Omnipod View app iOS widgets, which can be accessed by swiping right from the home screen, can be configured next to the Dexcom Continuous Glucose Monitoring (CGM) G6 app iOS widget, providing an easy view of PDM and CGM data on a single smartphone screen.

Bret Christensen, chief commercial officer, said: The Omnipod Dash mobile apps and widget capability are the first of their kind when it comes to monitoring insulin pump data and we are excited to bring this combined view of insulin delivery and Dexcom CGM data to our users. People look at their mobile phone countless times throughout the day and now Omnipod Dash users are able to conveniently and discreetly check their diabetes status or that of their loved ones', in order to stay well-informed, help make diabetes management decisions, and make diabetes a smaller part of life.

How secure is any data that is captured by it?

The Omnipod System is an FDA-regulated medical device and has to be secure and it received ISO 27001 certification of its Omnipod DASH System in November 2018.

Around that same time, the Omnipod DASH system also receivedDTSec (Diabetes Technology Societys) Cybersecurity Standard for Connected Diabetes Device Security certification.Insuletis the only insulin pump company to have both certifications.

DTSec leverages ISO/IEC 15408 to provide a framework for risk-based, multi-stakeholder definition of security requirements. The Omnipod DASH System, Insulets next-generation platform, was designed to be the foundation for the companys future innovation. With the ISO 27001 and DTSec certifications, the Omnipod DASH System is now globally recognised for incorporating the highest standards for information and cyber security and safety, including secure data transfer between the Pod and the personal diabetes manager (PDM), as well as secure cloud storage.

Insulet CEO, Shacey Petrovic, added: With last years launch of Omnipod Dash we created our online training program for DASH customers transitioning from Omnipod. This enables users to get started with online training without the need to leave home or meet with a clinician for support. Thanks to Dashs simplicity, this web-based training has been a success and today it is being used extensively to support thousands of users and, in fact, many users transitioning from Omnipod to Omnipod Dash just rely on the intuitive user interface which provides step by step instructions to get started. These tools were created to support effective scaling of our business and have proven to be exceptionally helpful in our current environment.

Read the rest here:
How a tubeless device provides three days of non-stop insulin delivery - Med-Tech Innovation

Weight, blood pressure and blood fat elevations are greater in young people who develop type 2 diabetes according to scientists at the Universities of Glasgow and Manchester.

The study, published in Diabetologia, examined known risk factors for heart disease between people with and without type 2 diabetes at similar ages. Its findings confirm that younger people diagnosed with diabetes have a greater difference in weight relative to people without the disease.

The difference in weight between those with and without type 2 diabetes was most marked for white people, especially women. The same was also true for blood pressure: young, White people had a higher difference in blood pressure when diagnosed with type 2 diabetes when measured against those without the disease. While the work confirmed the same patterns were seen in South Asian and Black people, these groups tended to develop type 2 diabetes at much lower BMIs, with less difference in weight between those who did and did. Similar, though less marked patterns by age were seen for blood fat levels.

Previous studies have shown that there is a greater loss of life from type 2 diabetes in White people, and the researchers believe these findings may help to explain why.

Overall the researchers found that the difference in weight for individuals with and without type 2 diabetes was 20kg, between the ages of 20 and 39 years old. While for those diagnosed over 80 years old, the weight difference was only 5kg. Similarly, the difference in blood pressure was highest in the younger age bracket for those who were diagnosed with type 2 diabetes. There was no difference in blood pressure for those with or without type 2 diabetes at over 80 years old.

People who develop diabetes at a younger age develop more complications over their lifetime, and die younger than people who develop diabetes much later in life. However scientists still dont fully understand why this is case.

Researchers say these findings may explain why younger onset of type 2 diabetes could be more damaging to some individuals, as they develop it on top of other health risk factors.

Professor Naveed Sattar of the University of Glasgow, who led the study, said: Our findings could help explain why younger diabetes onset is more damaging, and offer important insights into different groups for the development of type 2 diabetes.

They also suggest a need for greater healthcare emphasis on diabetes and heart disease management in young people developing diabetes, regardless of their sex or ethnicity.

Prof Martin K Rutter of The University of Manchester, and Manchester University NHS Foundation Trust, who col-led the study, said, Our work also helps to understand why there may be a greater loss of life from type 2 diabetes in White people as we noted that risk factors differences between those with and without diabetes, across nearly all ages, were less in South Asians and Black people compared to White people

Our study also further illustrates how South Asians and Black people are more sensitive to the adverse metabolic effects of weight gain than Whites. These findings may hold some relevance to the current COVID-19 findings where people with diabetes, and of specific ethnicities, are at greater risk for severe outcomes.

The researchers used the UK Clinical Practice Research Datalink to identify 187,601 people with type 2 diabetes diagnosed between 19982015 in England. The study compared their weight and blood pressure at diagnosis with age-matched people without diabetes, by sex and ethnic group.

The study, Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA1c and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes is published in Diabetologia, a journal of the European Association for the Study of Diabetes. The work was funded by Diabetes UK.

The paper is available here: https://link.springer.com/article/10.1007/s00125-020-05169-6

See original here:
Weight and blood pressure greater in young people who develop type 2 diabetes - Mirage News

May 26, 2020 @ 10:30 by Chloe Holmes

The International Centre for Life in Newcastle upon Tyne, UK, celebrates its 20th anniversary on May 27 with a week of virtual events and activities.

The landmark anniversary for Life home to the popular visitor attraction Life Science Centre, biomedical research facilities and two NHS clinics falls during VisitEnglands English Tourism Week, which this year will focus on supporting the recovery of tourism and raise awareness of the importance, quality and value of the sector to the UK economy.

Lifes Chief Executive, Linda Conlon, said: We had big plans in place to celebrate Life being 20 in 2020, but weve quickly adapted our operations and celebrations to a digital format. Like many others, we will continue to celebrate our birthday under lockdown it just takes a bit more ingenuity and creativity to do so, and theyre skills that lie at the heart of science.

Over the past 20 years, Life has been home to the research team that created the worlds first cloned human embryo; the first fertility clinic in the world licensed to treat patients using mitochondrial replacement therapy, which was also researched and developed onsite; and a pioneering stem cell treatment that has restored the sight of many people. Now, researchers are working onsite to help tackle the COVID-19 pandemic.

Life Science Centre welcomes about 300,000 visitors a year inspiring the next generation of scientists and health heroes, and helping people of all ages to explore science and to discover its relevance to their own lives.

Linda said: The mission of Life Science Centre has never been more crucial than it is today, in the midst of a global pandemic and climate crisis. Science centres can play a valuable role in communicating cutting-edge science to the public.

Lifes virtual celebrations start today [Tuesday 26 May], with a birthday-themed making activity for families to take part in for #LifeGoesONline on Facebook, Twitter or Instagram. For adults, later this evening, Life will host a science-themed virtual pub quiz.

Follow this link:
Life celebrates 20th anniversary during English Tourism Week - North East Times

New York, May 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Organ and Tissue Transplantation Industry" - https://www.reportlinker.com/p05379582/?utm_source=GNW An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Kidney market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 1.8% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over 717 Number of Transplants to the regions size over the next 7 to 8 years. In addition, over 780.1 Number of Transplants worth of projected demand in the region will come from Rest of European markets. In Japan, the Kidney segment will reach a market size of 6 Thousand Number of Transplants by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Organ and Tissue Transplantation market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the worlds second largest economy will grow at 5.8% over the next couple of years and add approximately 10.2 Thousand Number of Transplants in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Organ and Tissue Transplantation market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others, Acelity L.P. Inc.; CryoLife, Inc.; Dr. Franz Khler Chemie GmbH; Exactech, Inc.; Organ Recovery Systems; Organ Transport Systems; Organogenesis, Inc.; XVIVO Perfusion AB

Read the full report: https://www.reportlinker.com/p05379582/?utm_source=GNW

ORGAN AND TISSUE TRANSPLANTATION MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JUNE 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Market Outlook Recent Market Activity Current & Future Analysis A Review of Organ Donors Worldwide Demand and Supply Imbalance Measures to Address Organ Shortage Cardiac Arrest Death Patients: The Untapped Potential Donors Donation after Circulatory Death - Rife with Ethical Issues Transplantation - Expenditure and Regional Variations Bone Grafts: An Overview Orthopedic Grafts - Regional Market Variations Global Competitor Market Shares Organ and Tissue Transplantation Competitor Market Share Scenario Worldwide (in %): 2018 & 2029 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS Acelity L.P. Inc. (USA) CryoLife, Inc. (USA) Exactech, Inc. (USA) Dr. Franz Khler Chemie GmbH (Germany) Organogenesis, Inc. (USA) Organ Recovery Systems (USA) Organ Transport Systems (USA) XVIVO Perfusion AB (Sweden) 3. MARKET TRENDS & DRIVERS Combined Organ Transplantation - Gaining Attention Illegal Organ Trafficking - A Risky Proposition Transplant Tourism - Creating Brighter Avenues Graying Population and Chronic Diseases Surge Need for Transplants Optimization Strategies for Organs Catch Attention and Supply- Demand Gap Widens Advent of Innovative Devices Mitigate Chances of Organ Damages Investment Opportunities Rise for Allied Fields as Organ Transplantation Market Grows Shortage of Organs Propels Research on Xenotransplantation A Peek into the Organ Transplant Immunosuppressants Market Market to Come Under Tremendous Pressure Rising Incidences of Degenerative Intervertebral Disc Diseases Promote Tissue Transplantation Fetal Tissue for Bionic Devices - Assuming Importance LVADs - Gaining Significance for Impending Heart Transplants Synthetic Bone Graft - The Latest Trend Stem Cell Therapies - Expanding the Horizon of Transplantation Rising Cancer Incidence to Drive Stem Cell Transplants Demineralized Bone Matrix (DBM): Strong Growth but Tough Competition Bone Morphogenetic Protein - Safety Concerns Affect Growth Prospects Dental Bone Grafting - A High Potential Market Key Recent Technological Innovations 3-D Bioprinting Preloaded Corneal Tissue Cartridges Lung Perfusion Technology 4. GLOBAL MARKET PERSPECTIVE Table 1: Organ and Tissue Transplantation Global Market Estimates and Forecasts in Number of Transplants by Region/Country: 2020-2027 Table 2: Organ and Tissue Transplantation Global Retrospective Market Scenario in Number of Transplants by Region/Country: 2012-2019 Table 3: Organ and Tissue Transplantation Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 Table 4: Kidney (Organ) World Market by Region/Country in Number of Transplants : 2020 to 2027 Table 5: Kidney (Organ) Historic Market Analysis by Region/Country in Number of Transplants : 2012 to 2019 Table 6: Kidney (Organ) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 Table 7: Liver (Organ) Potential Growth Markets Worldwide in Number of Transplants : 2020 to 2027 Table 8: Liver (Organ) Historic Market Perspective by Region/Country in Number of Transplants : 2012 to 2019 Table 9: Liver (Organ) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027 Table 10: Heart (Organ) Geographic Market Spread Worldwide in Number of Transplants : 2020 to 2027 Table 11: Heart (Organ) Region Wise Breakdown of Global Historic Demand in Number of Transplants : 2012 to 2019 Table 12: Heart (Organ) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 Table 13: Other Organs (Organ) World Market Estimates and Forecasts by Region/Country in Number of Transplants : 2020 to 2027 Table 14: Other Organs (Organ) Market Historic Review by Region/Country in Number of Transplants : 2012 to 2019 Table 15: Other Organs (Organ) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Organ and Tissue Transplantation Market Share (in %) by Company: 2018 & 2025 Market Analytics Table 16: United States Organ and Tissue Transplantation Market Estimates and Projections in Number of Transplants by Organ: 2020 to 2027 Table 17: Organ and Tissue Transplantation Market in the United States by Organ: A Historic Review in Number of Transplants for 2012-2019 Table 18: United States Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 CANADA Table 19: Canadian Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2to 2027 Table 20: Canadian Organ and Tissue Transplantation Historic Market Review by Organ in Number of Transplants : 2012-2019 Table 21: Organ and Tissue Transplantation Market in Canada: Percentage Share Breakdown of Sales by Organ for 2012, 2020, and 2027 JAPAN Table 22: Japanese Market for Organ and Tissue Transplantation: Annual Sales Estimates and Projections in Number of Transplants by Organ for the Period 2020-2027 Table 23: Organ and Tissue Transplantation Market in Japan: Historic Sales Analysis in Number of Transplants by Organ for the Period 2012-2019 Table 24: Japanese Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 CHINA Table 25: Chinese Organ and Tissue Transplantation Market Growth Prospects in Number of Transplants by Organ for the Period 2020-2027 Table 26: Organ and Tissue Transplantation Historic Market Analysis in China in Number of Transplants by Organ: 2012-2019 Table 27: Chinese Organ and Tissue Transplantation Market by Organ: Percentage Breakdown of Sales for 2012, 2020, and 2027 EUROPE Market Facts & Figures European Organ and Tissue Transplantation Market: Competitor Market Share Scenario (in %) for 2018 & 2025 Market Analytics Table 28: European Organ and Tissue Transplantation Market Demand Scenario in Number of Transplants by Region/Country: 2020-2027 Table 29: Organ and Tissue Transplantation Market in Europe: A Historic Market Perspective in Number of Transplants by Region/Country for the Period 2012-2019 Table 30: European Organ and Tissue Transplantation Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 Table 31: European Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2020-2027 Table 32: Organ and Tissue Transplantation Market in Europe in Number of Transplants by Organ: A Historic Review for the Period 2012-2019 Table 33: European Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 FRANCE Table 34: Organ and Tissue Transplantation Market in France by Organ: Estimates and Projections in Number of Transplants for the Period 2020-2027 Table 35: French Organ and Tissue Transplantation Historic Market Scenario in Number of Transplants by Organ: 2012-2019 Table 36: French Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 GERMANY Table 37: Organ and Tissue Transplantation Market in Germany: Recent Past, Current and Future Analysis in Number of Transplants by Organ for the Period 2020-2027 Table 38: German Organ and Tissue Transplantation Historic Market Analysis in Number of Transplants by Organ: 2012-2019 Table 39: German Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 ITALY Table 40: Italian Organ and Tissue Transplantation Market Growth Prospects in Number of Transplants by Organ for the Period 2020-2027 Table 41: Organ and Tissue Transplantation Historic Market Analysis in Italy in Number of Transplants by Organ: 2012-2019 Table 42: Italian Organ and Tissue Transplantation Market by Organ: Percentage Breakdown of Sales for 2012, 2020, and 2027 UNITED KINGDOM Table 43: United Kingdom Market for Organ and Tissue Transplantation: Annual Sales Estimates and Projections in Number of Transplants by Organ for the Period 2020-2027 Table 44: Organ and Tissue Transplantation Market in the United Kingdom: Historic Sales Analysis in Number of Transplants by Organ for the Period 2012-2019 Table 45: United Kingdom Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 SPAIN Table 46: Spanish Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2to 2027 Table 47: Spanish Organ and Tissue Transplantation Historic Market Review by Organ in Number of Transplants : 2012-2019 Table 48: Organ and Tissue Transplantation Market in Spain: Percentage Share Breakdown of Sales by Organ for 2012, 2020, and 2027 RUSSIA Table 49: Russian Organ and Tissue Transplantation Market Estimates and Projections in Number of Transplants by Organ: 2020 to 2027 Table 50: Organ and Tissue Transplantation Market in Russia by Organ: A Historic Review in Number of Transplants for 2012-2019 Table 51: Russian Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 REST OF EUROPE Table 52: Rest of Europe Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2020-2027 Table 53: Organ and Tissue Transplantation Market in Rest of Europe in Number of Transplants by Organ: A Historic Review for the Period 2012-2019 Table 54: Rest of Europe Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 ASIA-PACIFIC Table 55: Asia-Pacific Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Region/Country: 2020-2027 Table 56: Organ and Tissue Transplantation Market in Asia-Pacific: Historic Market Analysis in Number of Transplants by Region/Country for the Period 2012-2019 Table 57: Asia-Pacific Organ and Tissue Transplantation Market Share Analysis by Region/Country: 2012 VS 2020 VS 2027 Table 58: Organ and Tissue Transplantation Market in Asia-Pacific by Organ: Estimates and Projections in Number of Transplants for the Period 2020-2027 Table 59: Asia-Pacific Organ and Tissue Transplantation Historic Market Scenario in Number of Transplants by Organ: 2012-2019 Table 60: Asia-Pacific Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 AUSTRALIA Table 61: Organ and Tissue Transplantation Market in Australia: Recent Past, Current and Future Analysis in Number of Transplants by Organ for the Period 2020-2027 Table 62: Australian Organ and Tissue Transplantation Historic Market Analysis in Number of Transplants by Organ: 2012-2019 Table 63: Australian Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 INDIA Table 64: Indian Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2to 2027 Table 65: Indian Organ and Tissue Transplantation Historic Market Review by Organ in Number of Transplants : 2012-2019 Table 66: Organ and Tissue Transplantation Market in India: Percentage Share Breakdown of Sales by Organ for 2012, 2020, and 2027 SOUTH KOREA Table 67: Organ and Tissue Transplantation Market in South Korea: Recent Past, Current and Future Analysis in Number of Transplants by Organ for the Period 2020-2027 Table 68: South Korean Organ and Tissue Transplantation Historic Market Analysis in Number of Transplants by Organ: 2012-2019 Table 69: Organ and Tissue Transplantation Market Share Distribution in South Korea by Organ: 2012 VS 2020 VS 2027 REST OF ASIA-PACIFIC Table 70: Rest of Asia-Pacific Market for Organ and Tissue Transplantation: Annual Sales Estimates and Projections in Number of Transplants by Organ for the Period 2020-2027 Table 71: Organ and Tissue Transplantation Market in Rest of Asia-Pacific: Historic Sales Analysis in Number of Transplants by Organ for the Period 2012-2019 Table 72: Rest of Asia-Pacific Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 LATIN AMERICA Table 73: Latin American Organ and Tissue Transplantation Market Trends by Region/Country in Number of Transplants : 2020-2027 Table 74: Organ and Tissue Transplantation Market in Latin America in Number of Transplants by Region/Country: A Historic Perspective for the Period 2012-2019 Table 75: Latin American Organ and Tissue Transplantation Market Percentage Breakdown of Sales by Region/Country: 2012, 2020, and 2027 Table 76: Latin American Organ and Tissue Transplantation Market Growth Prospects in Number of Transplants by Organ for the Period 2020-2027 Table 77: Organ and Tissue Transplantation Historic Market Analysis in Latin America in Number of Transplants by Organ: 2012-2019 Table 78: Latin American Organ and Tissue Transplantation Market by Organ: Percentage Breakdown of Sales for 2012, 2020, and 2027 ARGENTINA Table 79: Argentinean Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2020-2027 Table 80: Organ and Tissue Transplantation Market in Argentina in Number of Transplants by Organ: A Historic Review for the Period 2012-2019 Table 81: Argentinean Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 BRAZIL Table 82: Organ and Tissue Transplantation Market in Brazil by Organ: Estimates and Projections in Number of Transplants for the Period 2020-2027 Table 83: Brazilian Organ and Tissue Transplantation Historic Market Scenario in Number of Transplants by Organ: 2012-2019 Table 84: Brazilian Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 MEXICO Table 85: Organ and Tissue Transplantation Market in Mexico: Recent Past, Current and Future Analysis in Number of Transplants by Organ for the Period 2020-2027 Table 86: Mexican Organ and Tissue Transplantation Historic Market Analysis in Number of Transplants by Organ: 2012-2019 Table 87: Mexican Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 REST OF LATIN AMERICA Table 88: Rest of Latin America Organ and Tissue Transplantation Market Estimates and Projections in Number of Transplants by Organ: 2020 to 2027 Table 89: Organ and Tissue Transplantation Market in Rest of Latin America by Organ: A Historic Review in Number of Transplants for 2012-2019 Table 90: Rest of Latin America Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2VS 2027 MIDDLE EAST Table 91: The Middle East Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Region/Country: 2020-2027 Table 92: Organ and Tissue Transplantation Market in the Middle East by Region/Country in Number of Transplants : 2012-2019 Table 93: The Middle East Organ and Tissue Transplantation Market Share Breakdown by Region/Country: 2012, 2020, and 2027 Table 94: The Middle East Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2020 to 2027 Table 95: The Middle East Organ and Tissue Transplantation Historic Market by Organ in Number of Transplants : 2012-2019 Table 96: Organ and Tissue Transplantation Market in the Middle East: Percentage Share Breakdown of Sales by Organ for 2012,2020, and 2027 IRAN Table 97: Iranian Market for Organ and Tissue Transplantation: Annual Sales Estimates and Projections in Number of Transplants by Organ for the Period 2020-2027 Table 98: Organ and Tissue Transplantation Market in Iran: Historic Sales Analysis in Number of Transplants by Organ for the Period 2012-2019 Table 99: Iranian Organ and Tissue Transplantation Market Share Analysis by Organ: 2012 VS 2020 VS 2027 ISRAEL Table 100: Israeli Organ and Tissue Transplantation Market Estimates and Forecasts in Number of Transplants by Organ: 2020-2027 Table 101: Organ and Tissue Transplantation Market in Israel in Number of Transplants by Organ: A Historic Review for the Period 2012-2019 Table 102: Israeli Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 SAUDI ARABIA Table 103: Saudi Arabian Organ and Tissue Transplantation Market Growth Prospects in Number of Transplants by Organ for the Period 2020-2027 Table 104: Organ and Tissue Transplantation Historic Market Analysis in Saudi Arabia in Number of Transplants by Organ: 2012-2019 Table 105: Saudi Arabian Organ and Tissue Transplantation Market by Organ: Percentage Breakdown of Sales for 2012, 2020, and 2027 UNITED ARAB EMIRATES Table 106: Organ and Tissue Transplantation Market in the United Arab Emirates: Recent Past, Current and Future Analysis in Number of Transplants by Organ for the Period 2020-2027 Table 107: United Arab Emirates Organ and Tissue Transplantation Historic Market Analysis in Number of Transplants by Organ: 2012-2019 Table 108: Organ and Tissue Transplantation Market Share Distribution in United Arab Emirates by Organ: 2012 VS 2020 VS 2027 REST OF MIDDLE EAST Table 109: Organ and Tissue Transplantation Market in Rest of Middle East: Recent Past, Current and Future Analysis in Number of Transplants by Organ for the Period 2020-2027 Table 110: Rest of Middle East Organ and Tissue Transplantation Historic Market Analysis in Number of Transplants by Organ: 2012-2019 Table 111: Rest of Middle East Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 AFRICA Table 112: African Organ and Tissue Transplantation Market Estimates and Projections in Number of Transplants by Organ: 2020 to 2027 Table 113: Organ and Tissue Transplantation Market in Africa by Organ: A Historic Review in Number of Transplants for 2012-2019 Table 114: African Organ and Tissue Transplantation Market Share Breakdown by Organ: 2012 VS 2020 VS 2027 IV. COMPETITION

Total Companies Profiled: 19 Read the full report: https://www.reportlinker.com/p05379582/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more from the original source:
Amid the COVID-19 crisis and the looming economic recession, the Organ and Tissue Transplantation market worldwide will grow by a projected 30.8...

Pune, May 27, 2020 (GLOBE NEWSWIRE) -- The global regenerative medicine market size is expected to reach USD 151,949.5 billion by 2026, exhibiting a CAGR of 26.1% during the forecast period. The growing R&D investment by key players for the development of innovative regenerative therapies can be a vital factor enabling the growth of the market during the forecast period, states Fortune Business Insights in a report, titled Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 2026 the market size stood at USD 23,841.5 Million in 2018. The growing organ transplantation surgeries will spur opportunities for the market during the forecast period.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Market Driver:

Escalating Cases of Genetic Disorders to Augment Growth

The increasing prevalence of chronic disorders can be an essential factor enabling the growth of the market. Similarly, the growing incidence of genetic disorders will fuel demand for the market. The growing investment in R&D activities by major market players will have a positive impact on the regenerative medicine market growth during the forecast period. For instance, in March 2018, SanBio Group, a leader in regenerative medicine and therapies for neurological disorders announced that it has made a deal with Hitachi Chemical Advanced Therapeutics Solutions, LLC, a cell manufacturing company for the development and manufacturing of innovative regenerative medicines.

Furthermore, the rising cases of neurological disorders will influence the healthy growth of the market. The growing healthcare expenditure in developed and developing countries will boost the market in the forthcoming years. The ongoing clinical trials and robust pipeline products in stem cell andgene therapy will contribute tremendously to the growth of the market. The rising utilization of skin substitutes, grafts, bone matrix, and other tissue-engineered regenerative medicine in orthopedic and neurosurgical applications will augment the growth of the market.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

Regional Analysis:

Development of Novel Therapies to Favor Growth in North America

The market in North America generated a revenue of USD 9,128.2 million in 2018 and is predicted to grow rapidly during the forecast period owing to the presence of major pharmaceutical companies. The growing launch of novel therapeutics and the availability of advanced technologies along with clinical trials will support growth in North America. Asia Pacific is expected to witness a high growth rate during the forecast period owing to the

developing healthcare infrastructure and facilities. The increasing stem cell research in developing countries such as India, Japan China will contribute positively to the growth of the market. For instance, In April 2013, the Japan Ministry of Health, Labor, and Welfare approved Regenerative Medicine law. The growing number of clinical developments of regenerative and cell-based therapies will drive the market in the region. The increasing government initiatives for human embryonic stem cell research and development will further encourage growth in the region. The surge in geriatric patients, the evolving lifestyle of people, and the growing need for novel therapies are factors likely to aid the expansion of the market in Asia Pacific.

Quick Buy - Regenerative Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100970

Key Development:

2018: Novartis announced that it has received EUs approval for one-time gene therapy Luxturna, to restore vision in people with rare and genetically-associated retinal disease.

List of the Key Companies Operating in the Regenerative Medicine Market are:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/regenerative-medicine-market-100970

Detailed Table of Content:

TOC Continued.!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

Have a Look at Related Reports:

Gene Therapy Market Size, Share and Global Trend By Disease Indication(Cancer, Genetic disorders, Cardiovascular diseases, Ophthalmology, Neurological conditions) By Type of Vectors (Viral vectors, Non-viral vectors), By Type of Cells(Somatic cells, Germline cells) and Geography Forecast till 2026

Induced Pluripotent Stem Cells Market Size, Share and Global Trend By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education & research institutes, Biotechnological companies) and Geography Forecast till 2026

Platelet Rich Plasma Market Size, Share And Global Trend By Origin (Allogeneic, Autologous, Homologous), By Type (Pure PRP, Leukocyte rich PRP, Leukocyte rich fibrin), By Application (Orthopaedic surgery, Cosmetic surgery, General surgery, Neurosurgery, Others), And Geography Forecast Till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/regenerative-medicine-market-9183

Go here to see the original:
Regenerative Medicine Market to Exhibit a CAGR of 26.1% by 2026; Rising Prevalence of Genetic Disorders to Fuel Demand, states Fortune Business...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing prevalence of chronic diseases has been instrumental in driving the growth of the market.

Regenerative Medicine Market 2020-2024: Segmentation

Regenerative Medicine Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Regenerative Medicine Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our regenerative medicine market report covers the following areas:

This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.

Regenerative Medicine Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. Backed with competitive intelligence and benchmarking, our research reports on the regenerative medicine market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Regenerative Medicine Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Research Report with COVID-19 Forecasts - Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth |...

Pessac, France Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of NextGeneration Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a bioprinted skin substitute in collaboration with the Assistance Publique Hpitaux de Marseille. Poietis appoints Dr. Geoffrey Gurtner, MD, Johnson and Johnson Professor of Surgery, Professor of Materials Science and Engineering at Stanford University and Vice-Chairman of Surgery for Innovation at Stanford University School of Medicine (California, United States) and Dr. Michael H. May, President & CEO of the Center for Commercialization of Regenerative Medicine (CCRM) at Toronto (Canada).

The formation of Poietis SAB is a very important step towards company global deployment in the clinical area says Bruno Brisson, Poietis co-founder and VP Business Development. We are delighted to welcome Dr. Gurtner and Dr. May to our SAB, where they will be key contributors in further enhancing our efforts to bring bioprinting solutions to clinicians and patients with high unmet needs.

To have Dr. Gurtner, a world-renowned expert in tissue-engineering therapies for skin wound healing, join our SAB will enrich our R&D efforts to achieve the first-in-human of a bioprinted skin substitute in the coming years adds Dr. Fabien Guillemot, CEO and Poietis founder. We also believe Dr. May will prove invaluable to Poietis leadership team, and we look forward to his insights and guidance to accelerate the advancement of our bioprinting platform technology to address the key challenges in tissue manufacturing and regenerative medicine.

3D bioprinting is a once-in-a-generation transformative technology. By focusing its 3D printing platform on a clinical application of high unmet need, Poietis is leading the adoption of 3D printing in cell therapy and tissue engineering comments Dr. Michael H. May, PhD, President & CEO of the CCRM.

Dr. Geoffrey Gurtner, MD, is Johnson and Johnson Professor of Surgery and Professor of Materials Science and Engineering at Stanford University, California; USA. He currently serves as the Associate Chairman for Research in the Department of Surgery and is the Executive Director of the Stanford Wound Care Center.

Geoff is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California-San Francisco School of Medicine. He completed a general surgery residency at Massachusetts General Hospital, a plastic surgery residency at NYU School of Medicine and received advanced training in microsurgery at the University of Texas-MD Anderson Cancer Center. He is board certified in both general surgery and plastic surgery. He is the author of over 180 peer-reviewed publications in both scientific and surgical literature and editor for two major textbooks in the field: Grabb & Smiths Plastic Surgery and Plastic Surgery. Geoff was awarded the James Barrett Brown Award (for best paper in plastic surgery) in both 2009 and 2010, and has been named Researcher of the Year by the American Society of Plastic Surgeons and the American Association of Plastic Surgeons. His research has led to the development of several novel biomedical technologies. Geoff has co-founded several start-ups focused on wound healing, aesthetics and cardiovascular health.

Dr. Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship. He is President and Chief Executive Officer of the Center for Commercialization of Regenerative Medicine (CCRM) a Canadian public-private partnership supporting the translation and commercialization of cell & gene therapies and associated enabling technologies through stakeholder networks and with specialized teams, infrastructure and funding. He is also CEO of CCRM Enterprises, the venture creation and investment arm of CCRM.

Prior to CCRM, Michael was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity. Rimons initial focus was on advanced wound healing. Michael sits on a number of boards and advisory committees, including: the Entrepreneurship Leadership Council at the University of Toronto; the Commercialization Committee of the International Society for Cell and Gene Therapy, the Alliance for Regenerative Medicine Foundation, CellCan and AgeX Inc. He is Chair of ExcellThera and co-moderates sessions in the health streams of the Creative Destruction Labs.

*****

About Poietis: Bioprinting company specializing in the development of new biomanufacturing solutions, based on Laser-Assisted Bioprinting, for human tissues. Poietis mission is to provide clinicians and patients with tissue engineering therapies thanks to its innovative, proprietary Next-Generation Bioprinting platform (NGB). The multimodal NGB platform is declined in two versions: one for in vitro tissue engineering research (NGB-R) and a clinical version (NGB-C) for the production of implantable bioprinted tissues. This multi-modal, automated biomanufacturing platform enables researchers to achieve superior tissue through high resolution, and enables the fabrication of complex tissues with repeatability and reproducibility. Poietis bioprinting technology is the result of innovative research carried out over ten years at Inserm and the University of Bordeaux. Poietis won the iLab competition in 2014, the World Innovation Challenge Phase II in 2017 and recently the EY Disruptive Strategy Award. The company currently employs 35 people. More information: http://www.poietis.com Contact : bruno.brisson@poietis.com

Read more here:
Poietis Announces Formation of Scientific Advisory Board and Appoints Two First Prominent Regenerative Medicine Experts - BioSpace

MIAMI, May 27, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today a health update for two critically ill COVID-19 patients who were treated at Landmark Hospital in Athens, GA with the Companys Organicell Flow product. These patients were treated under the two recently approved Emergency Compassionate Use Investigational New Drug applications (eINDs) by the U.S. Food and Drug Administration (FDA).

Upon receiving FDA approval of the eIND on May 11, 2020, the Company and Landmark Hospital immediately treated the two critically ill COVID-19 patients, in their mid to late 70s, with Organicell Flow. Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data. These patients are no longer intubated, are alert and oriented with stable vital signs and oxygenation. Other organs such as the brain, heart and liver commonly affected in patients who had the SARS-CoV-2 virus have all shown progressive improvement in their function.

Dr. George Shapiro, Chief Medical Officer of Organicell stated, We are very pleased that Organicell Flow, administered intravenously, has to date met all of the primary objectives of safety and secondary clinical objectives of improved ICU status and reduction in the sequential organ failure assessment (SOFA) score.

Dr. Anthony Sagel, Chief of Medical Staff at Landmark hospital and treating physician for both patients said, The first patient has improved considerably and is now off the ventilator with normal appearing lungs on their chest X-ray. In addition, their mental status continues to improve along with normal kidney function. The second patient has also been systemically improving, including their kidney and respiratory function. Their acute delirium has improved, and is communicating well with family. Both patients are ready to be discharged from the ICU.

Worldwide clinical experiences have shown that the progressive decline in lung function is the main cause of death in patients infected with COVID-19 disease, and patients who are admitted to the ICU requiring mechanical ventilation (Intubation) has revealed high mortality rates. Both patients in the current study were severely ill with underlying health conditions and severe multi-organ failure. Under the defined protocols of the clinical trials, each of the above patients will continue to be monitored on their health vitals for a total period of 60 days. Based upon the continued favorable results, Organicell may seek other approvals to treat other severely ill patients.

About Organicell Regenerative Medicine, Inc.:

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The companys proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

About Landmark Hospitals:

Landmark provides solutions for patients who face a hospital discharge, yet still require acute medical care. These patients require a higher level of care for a longer period than the average hospital offers; but they are not yet ready to transfer to a sub-acute care facility. Landmark brings exciting new technologies and experienced management for the primary task of providing patients with the best medical care available as they continue their journey toward healing. For more information regarding Landmark Hospitals, visit https://www.landmarkhospitals.com.

Forward-Looking Statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the Securities Act), the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as will, believes, expects, potential or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:RooneyPartnersMarion Janic646-537-5649mjanic@rooneyco.com

Excerpt from:
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients - GlobeNewswire

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Takara Bio USA, Inc. (TBUSA) announced that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan. The CGCPII has been operational since January 2020.

The CGCPII is an expansion of the Center for Gene and Cell Processing (CGCP), which was established in 2014 and designed specifically for the safe, efficient manufacture of gene and cell therapy products. Both facilities have received ISO 9001 certification. The CGCPII provides additional capacity for Good Manufacturing Practice (GMP) viral vector production, process development, aseptic filling, and quality-testing facilities, as well as room for future expansion.

With the addition of the CGCPII, Takara Bio is able to accommodate the growing demand for gene and cell therapies and will continue to enhance its services for biopharmaceuticals and regenerative medicine products under GMP and Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP).

"Takara Bio is excited to increase our capacity to provide even more support to customers worldwide in the development of their regenerative medicine products. We have a history of developing products like RetroNectin reagent for regenerative medicine research, and we are building on that history with our expanded facility and service offerings," said Junichi Mineno, Chief Operating Officer, Takara Bio Inc.

With our state-of-the-art GMP manufacturing facilities in Japan and Europe, Takara Bio provides services for viral vector production, cell processing, clinical-grade human embryonic stem cell line derivation, quality testing, and cell banking. These gene and cell therapy manufacturing services, carried out by a global team of seasoned experts, provide support throughout the entire process of developing vital regenerative medicine products.

About Takara Bio

Takara Bio USA, Inc. (TBUSA) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.

Excerpt from:
Takara Bio Announces the Completion of a New GMP Facility for Manufacturing Gene and Cell Therapy Products - Business Wire